Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
6/9/2026, 12:00:00 AM
Merck and partner Gilead Sciences announced they are halting the Phase 3 EVOKE-03 trial on 2026-06-09; importance is estimated at Medium due to high expectations for Keytruda combination therapies, expected.
Korean Translation
2026-06-09 3상 EVOKE-03 임상 중단 발표. 키트루다 병용 요법에 대한 높은 기대치를 고려할 때 약 5% 이상의 부정적 영향이 예상되어 Medium으로 분류함, 예상됨.
Related Recent Events
Snowflake Inc (SNOW) · Earnings Release
Snowflake's next earnings release for Q2 fiscal year 2027 is scheduled for August 26, 2026, scheduled. This event is expected to have a medium impact as earnings reports typically drive price movements of at least 5%.
8/26/2026, 12:00:00 AM
Applied Materials Inc (AMAT) · Other
A quarterly dividend of $0.53 per share is expected, with an ex-dividend date of August 20, 2026. Low importance is assigned as standard dividend events typically result in a <5% price impact, expected.
8/20/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026, with medium importance estimated due to typical market volatility following results, scheduled.
8/18/2026, 12:00:00 AM
Keysight Technologies Inc (KEYS) · Earnings Release
Keysight's fiscal Q3 2026 earnings release is scheduled. Importance is estimated as Medium based on historical price volatility around earnings dates, scheduled.
8/18/2026, 12:00:00 AM
Applied Materials Inc (AMAT) · Earnings Release
The Q3 2026 earnings release is scheduled for August 13, 2026. Low importance is assigned as the announcement of a reporting date typically has a <5% price impact, scheduled.
8/13/2026, 12:00:00 AM
Cisco Systems Inc (CSCO) · Earnings Release
Cisco is scheduled to release its Q4 and full fiscal year 2026 earnings on August 12, 2026, scheduled. Market reaction estimated at ≥5% based on historical earnings volatility.
8/12/2026, 12:00:00 AM